NanoVibronix (NSDQ:NAOV) said today it inked a deal with the U.K.’s IMS Ultrasound to make it the exclusive U.K. distributor of its UroShield device, designed to prevent catheter-acquired urinary tract infections.
The UroShield device from the Elmsford, N.Y.-based company is designed to decrease pain and discomfort associated with urinary catheter use while also preventing bacterial colonization and biofilm on indwelling catheters to reduce UTIs.
“CAUTI is a major health concern in the UK and around the world, leading to extended hospital stays, increased costs, as well as increased patient mortality. We are excited to partner with NanoVibronix in order to bring UroShield to market in the UK, which we believe has enormous potential and could help save many lives. Given the strong supporting clinical data to date, we look forward to conducting an additional clinical trial in the UK with the support of NHS, which we believe will help garner even greater support from payors,” IMS Ultrasound managing director Andrew Wakeling said in a prepared statement.
As part of the deal, NanoVibronix said that IMS Ultrasound will also be funding a clinical study in association with the U.K.’s National Health Service.
“We are excited to report the addition of a significant European distributor partnership for UroShield following our recently announced preliminary clinical results, which demonstrate a material reduction in the rate of CAUTI. UroShield already has European marketing clearance, and this latest data is now helping us to attract the leading distributors across Europe. The fact IMS Ultrasound is willing to fully fund the planned clinical trial in the UK is strong validation of their interest and commitment to our UroShield product,” NanoVibronix CEO Brian Murphy said in a press release.
Last month, NanoVibronix released interim results from a trial of its UroShield ultrasound device designed to prevent bacteria and biofilms from forming on urinary catheters, touting a low rate of CAUTIs.